Stockscreener 앱 받기
4.42
2.22%
-0.16
시간 외 거래:
4.48
0.06
+1.36%
전일 마감가:
$4.58
열려 있는:
$4.54
하루 거래량:
93,809
Relative Volume:
0.42
시가총액:
$211.04M
수익:
-
순이익/손실:
$-293.42M
주가수익비율:
-0.1516
EPS:
-29.1639
순현금흐름:
$-14.87M
1주 성능:
-3.07%
1개월 성능:
+4.88%
6개월 성능:
-30.57%
1년 성능:
+99.03%
1일 변동 폭
$4.40
$4.58
1주일 범위
$3.84
$4.79
52주 변동 폭
$1.93
$12.46
미네르바 뉴로사이언스 Stock (NERV) Company Profile
명칭
Minerva Neurosciences Inc
전화
617-600-7373
주소
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
4.42 | 218.68M | 0 | -293.42M | -14.87M | -29.16 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
미네르바 뉴로사이언스 Stock (NERV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 개시 | Citizens | Mkt Outperform |
| 2020-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 개시 | BTIG Research | Buy |
| 2019-10-02 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-25 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-31 | 개시 | H.C. Wainwright | Buy |
| 2017-09-01 | 개시 | Citigroup | Buy |
| 2017-03-06 | 재개 | Jefferies | Buy |
| 2016-05-12 | 재개 | Jefferies | Buy |
모두보기
미네르바 뉴로사이언스 주식(NERV)의 최신 뉴스
NERV Upgraded by Jefferies -- Price Target Raised to $10.00 - GuruFocus
Minerva Neurosciences (NASDAQ:NERV) Downgraded to Strong Sell Rating by Zacks Research - marketbeat.com
Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway By Investing.com - Investing.com Canada
Minerva Neurosciences, Inc (NASDAQ:NERV) Given Consensus Recommendation of "Reduce" by Brokerages - marketbeat.com
Balyasny Asset Management (NERV) discloses 9.99% Minerva Neurosciences ownership via shares and warrants - Stock Titan
Farallon group discloses 9.7% Minerva Neurosciences (NERV) holding via shares and warrants - Stock Titan
Minerva Neurosciences Elevates Aliquo to Accounting Leadership - TipRanks
Minerva Neurosciences (NERV) elevates Anthony Aliquo to chief accounting officer role - Stock Titan
HC Wainwright Has Bearish Estimate for NERV Q3 Earnings - marketbeat.com
H.C. Wainwright Maintains Minerva Neurosciences(NERV.US) With Hold Rating, Maintains Target Price $7 - Moomoo
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Minerva Neurosciences (NERV) and Zymeworks (ZYME) - The Globe and Mail
Minerva Neurosciences (NASDAQ:NERV) Upgraded at Wall Street Zen - MarketBeat
Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Form 8K Minerva Neurosciences Inc For: 7 August By Investing.com - Investing.com Nigeria
Minerva Neurosciences Q2 adjusted EPS beats estimates on warrant gain - scanx.trade
Minerva Neurosciences Provides Second Quarter 2026 Financial Results And Business Updates - TradingView
Minerva Neurosciences, Inc. Q2 2026: Net income $17.47M, EPS $(0.14) — 10-Q Summary - TradingView
Minerva Neurosciences (NASDAQ: NERV) logs $107.9M loss but holds $75.4M cash - Stock Titan
Minerva Neurosciences posts Q2 2026 results: GAAP net income $17.5M; cash & equivalents $75.4M - TradingView
Minerva Neurosciences: Q2 Earnings Snapshot - marketscreener.com
Minerva Neurosciences reports $17.5 million Q2 net income as Phase 3 trial continues - Quiver Quantitative
Minerva Neurosciences (Nasdaq: NERV) swings to Q2 profit on warrant gain - Stock Titan
Minerva's schizophrenia trial is designed to enroll 380 patients - Stock Titan
Janus Henderson Group PLC Increases Stock Position in Minerva Neurosciences, Inc $NERV - MarketBeat
Form 4 Minerva Neurosciences Inc For: 3 August By Investing.com - Investing.com Nigeria
Minerva Neurosciences (NERV) awards options tied to Phase 3 trial - Stock Titan
NERV Q2'26 Earnings: EPS estimate is (0.19) USD - TradingView
Seven Fleet Capital Management LP Makes New Investment in Minerva Neurosciences, Inc $NERV - marketbeat.com
NERV Q2'26 Earnings: revenue estimate is 0 USD - TradingView
NERV|Minerva Neurosciences Inc|Price:4.205| - TradingKey
Minerva Neurosciences Inc (NERV) Cash Flow - TradingKey
Minerva Neurosciences Inc (NERV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Minerva Neurosciences Inc (NERV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Minerva Neurosciences Inc (NERV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Minerva Neurosciences Inc Revenue Breakdown – FWB:4MNA - TradingView
Minerva Neurosciences Inc (NERV) Institutional Confidence - TradingKey
NERV Options Chain — NASDAQ:NERV - TradingView
NERV Options Volatility — NASDAQ:NERV - TradingView
ETFs Investing in Minerva Neurosciences Inc Stocks - TradingView
FEDERATED HERMES, INC. Acquires Additional Shares in Minerva Neu - GuruFocus
Federated Hermes reports 17.17% stake in Minerva (NASDAQ: NERV) - Stock Titan
Minerva Neurosciences (NERV) Slides 3.15% as Stock Tests Key Support at $4.52Iron Condor Alert - dars.gov.et
Minerva Neurosciences (NERV) Hovers Near Support as Trading Remains SubduedTICK Divergence - dars.gov.et
NERVMinerva Neurosciences Inc Options - Finviz
NERV News | MINERVA NEUROSCIENCES INC (NASDAQ:NERV) - ChartMill
Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2500 Growth Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2000 Index - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2000 Value Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell Microcap Value Benchmark Index - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2000 Growth Benchmark - marketscreener.com
미네르바 뉴로사이언스 (NERV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.20%
0.07%
자본화:
|
볼륨(24시간):